NasdaqCM - Delayed Quote USD

Capricor Therapeutics, Inc. (CAPR)

5.41 +0.26 (+5.05%)
At close: 4:00 PM EDT
5.53 +0.12 (+2.22%)
After hours: 6:52 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Frank Isaac Litvack FACC, M.D. Executive Chairman of the Board 120k -- 1956
Dr. Linda Marbán Ph.D. Co-Founder, President, CEO & Director 280.62k -- 1963
Mr. Anthony J. Bergmann M.B.A. CFO & Corporate Treasurer 437k -- 1986
Ms. Karen G. Krasney Executive VP, General Counsel & Secretary 426.72k -- 1953
Dr. Kristi A. H. Elliott Ph.D. Chief Science Officer -- -- --
Catherine Lee Kelleher Consultant -- -- --

Capricor Therapeutics, Inc.

10865 Road to the Cure
Suite 150
San Diego, CA 92121
United States
858 727 1755 https://www.capricor.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
101

Description

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.

Corporate Governance

Capricor Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024 - May 13, 2024
Capricor Therapeutics, Inc. Earnings Call

Related Tickers

ACXP Acurx Pharmaceuticals, Inc.
2.0700
+2.48%
 
HOOK HOOKIPA Pharma Inc.
0.8933
+10.82%
 
NGENF NervGen Pharma Corp.
1.5500
+3.33%
 
SLDB Solid Biosciences Inc.
8.98
+5.15%
 
ADTX Aditxt, Inc.
2.3900
-5.53%
 
ANL Adlai Nortye Ltd.
13.75
+2.15%
 
CYCC Cyclacel Pharmaceuticals, Inc.
1.5100
-5.63%
 
MDNAF Medicenna Therapeutics Corp.
1.8200
+30.00%
 
TARA Protara Therapeutics, Inc.
2.9250
-4.10%
 
INMB INmune Bio, Inc.
11.29
+4.15%